Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis
Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis
复制标题
DOI：
10.1159/000083832
复制
发表时间：
2003-01-01
影响因子：
--
通讯作者：
Mosnier, LO
中科院分区：
文献类型：
--
作者：
Bouma, BN;Mosnier, LO
凝血酶催化的血浆纤维蛋白原转化为纤维蛋白和形成不溶性纤维蛋白凝块是止血期间凝血级联的最后步骤。凝血和纤溶之间的微妙平衡决定了纤维蛋白凝块的稳定性。凝血酶激活的纤维蛋白溶解抑制剂（TAFI）在这一过程中起着重要作用。TAFI被凝血酶激活并保护纤维蛋白凝块免于溶解。讨论了TAFI在出血和血栓性疾病中的作用，以及其在伤口愈合和炎症中新出现的作用。版权所有（C）2004 S. Karger AG，巴塞尔。
The thrombin-catalysed conversion of plasma fibrinogen into fibrin and the development of an insoluble fibrin clot are the final steps of the coagulation cascade during haemostasis. A delicate balance between coagulation and fibrinolysis determines the stability of the fibrin clot. Thrombin Activatable Fibrinolysis Inhibitor (TAFI) plays an important role in this process. TAFI is activated by thrombin and protects the fibrin clot against lysis. The role of TAFI in bleeding and thrombotic disorders is discussed as well as its novel emerging role in wound healing and inflammation. Copyright (C) 2004 S. Karger AG, Basel.